Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2004 1
2005 1
2006 1
2007 1
2008 2
2010 2
2015 1
2016 2
2017 1
2018 3
2019 2
2020 3
2021 3
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L; CodeBreaK 200 Investigators. de Langen AJ, et al. Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7. Lancet. 2023. PMID: 36764316 Clinical Trial.
Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRAS(G12C) for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuva …
Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic dri …
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status.
Casale TB, Gimenez-Arnau AM, Bernstein JA, Holden M, Zuberbier T, Maurer M. Casale TB, et al. Dermatol Ther (Heidelb). 2023 Nov;13(11):2573-2588. doi: 10.1007/s13555-023-01040-9. Epub 2023 Sep 30. Dermatol Ther (Heidelb). 2023. PMID: 37776480 Free PMC article. Review.
Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. ...The hives may be big or small, may be warm to touch, may come and go, and may …
Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and …
Treating cancer-associated venous thromboembolism: A practical approach.
Van Cutsem E, Mahé I, Felip E, Agnelli G, Awada A, Cohen A, Falanga A, Mandala M, Peeters M, Tsoukalas N, Verhamme P, Ay C. Van Cutsem E, et al. Eur J Cancer. 2024 Sep;209:114263. doi: 10.1016/j.ejca.2024.114263. Epub 2024 Aug 5. Eur J Cancer. 2024. PMID: 39128187 Free article. Review.
Kangaroo care.
Wallace J, Ridpath-Parker J. Wallace J, et al. Qual Manag Health Care. 1993 Fall;2(1):1-5. Qual Manag Health Care. 1993. PMID: 10131016
Research suggests that Kangaroo Care is safe and that it is therapeutic for the infant and parent alike. The purpose of this article is to review the Kangaroo Care Program at Brigham and Women's Hospital and to illustrate how it meets the needs of parents of premature infa …
Research suggests that Kangaroo Care is safe and that it is therapeutic for the infant and parent alike. The purpose of this article …
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, Provencio M, Robinson A, Fülöp A, Rao SB, Camidge DR, Speranza G, Townson SM, Kobie J, Ayers M, Dettman EJ, Hunkapiller N, McDaniel R, Jung B, Burkhardt D, Mauntz R, Csőszi T. Bar J, et al. Lung Cancer. 2024 Apr;190:107506. doi: 10.1016/j.lungcan.2024.107506. Epub 2024 Feb 17. Lung Cancer. 2024. PMID: 38422883 Free article.
Fogarty International Center collaborative networks in infectious disease modeling: Lessons learnt in research and capacity building.
Nelson MI, Lloyd-Smith JO, Simonsen L, Rambaut A, Holmes EC, Chowell G, Miller MA, Spiro DJ, Grenfell B, Viboud C. Nelson MI, et al. Epidemics. 2019 Mar;26:116-127. doi: 10.1016/j.epidem.2018.10.004. Epub 2018 Oct 23. Epidemics. 2019. PMID: 30446431 Free PMC article. Review.
Here we reflect on the scientific achievements and lessons learnt from these programs (h-index = 106 for RAPIDD and 79 for MISMS), including the identification of outstanding researchers and fellows; funding flexibility for timely research workshops and working groups (particular …
Here we reflect on the scientific achievements and lessons learnt from these programs (h-index = 106 for RAPIDD and 79 for MISMS), including …
Treatment strategies of hospitalized patients with coronavirus disease-19.
Huang Y, Cai C, Zang J, Xie J, Xu D, Zheng F, Zhan T, Huang K, Wang Y, Wang X, Hu ZY, Deng Y, Xie Y. Huang Y, et al. Aging (Albany NY). 2020 Jun 17;12(12):11224-11237. doi: 10.18632/aging.103370. Epub 2020 Jun 17. Aging (Albany NY). 2020. PMID: 32554861 Free PMC article.
Of 238 patients 43.7% visited Wuhan, 58.4% got in touch with Wuhan people, and 47.5% had contacted with diagnosed patients. 37.8% patients had family members infected. 190 cases had mild / general disease, and 48 cases had severe / critical disease. ...
Of 238 patients 43.7% visited Wuhan, 58.4% got in touch with Wuhan people, and 47.5% had contacted with diagnosed patients. 37.8% pat …
Environmental Enrichment Sharpens Sensory Acuity by Enhancing Information Coding in Barrel Cortex and Premotor Cortex.
Zheng HJV, Meagher JP, Xu D, Patel YA, O'Connor DH, Kwon HB. Zheng HJV, et al. eNeuro. 2021 May 17;8(3):ENEURO.0309-20.2021. doi: 10.1523/ENEURO.0309-20.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 33893166 Free PMC article.
Thus, elucidating the neural mechanism underlying improvement of sensory stimulus discrimination is important for developing therapeutic strategies. We aim to advance the understanding of such neural mechanism. We found that tactile enrichment improved tactile stimulus fea …
Thus, elucidating the neural mechanism underlying improvement of sensory stimulus discrimination is important for developing therapeutic …
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.
Goldshtein H, Muhire A, Petel Légaré V, Pushett A, Rotkopf R, Shefner JM, Peterson RT, Armstrong GAB, Russek-Blum N. Goldshtein H, et al. Ann Clin Transl Neurol. 2020 Oct;7(10):1883-1897. doi: 10.1002/acn3.51174. Epub 2020 Sep 11. Ann Clin Transl Neurol. 2020. PMID: 32915525 Free PMC article.
RESULTS: When administered individually, Ciprofloxacin had a mild effect and Celecoxib had no therapeutic effect. However, combined Ciprofloxacin and Celecoxib (Cipro/Celecox) treatment caused a significant increase of ~ 84% in the distance the SOD1 G93R transgenic larvae …
RESULTS: When administered individually, Ciprofloxacin had a mild effect and Celecoxib had no therapeutic effect. However, combined C …
27 results